146 related articles for article (PubMed ID: 25841339)
1. Combined effect of microRNA, nutraceuticals and drug on pancreatic cancer cell lines.
Pandita A; Manvati S; Singh SK; Vaishnavi S; Bamezai RN
Chem Biol Interact; 2015 May; 233():56-64. PubMed ID: 25841339
[TBL] [Abstract][Full Text] [Related]
2. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.
Pandita A; Kumar B; Manvati S; Vaishnavi S; Singh SK; Bamezai RN
PLoS One; 2014; 9(9):e107154. PubMed ID: 25197966
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
4. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
5. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
Parasramka MA; Ali S; Banerjee S; Deryavoush T; Sarkar FH; Gupta S
Mol Nutr Food Res; 2013 Feb; 57(2):235-48. PubMed ID: 23293055
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
7. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2.
Park SH; Sung JH; Chung N
Mol Cell Biochem; 2014 Sep; 394(1-2):209-15. PubMed ID: 24894821
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells.
Shopit A; Li X; Wang S; Awsh M; Safi M; Chu P; Jia J; Al-Radhi M; Baldi S; Wang F; Fang J; Peng J; Ma X; Tang Z; Shu X
Phytomedicine; 2021 Oct; 91():153711. PubMed ID: 34450377
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
[TBL] [Abstract][Full Text] [Related]
14. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
17. Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress.
Cheng S; Swanson K; Eliaz I; McClintick JN; Sandusky GE; Sliva D
PLoS One; 2015; 10(4):e0122270. PubMed ID: 25915041
[TBL] [Abstract][Full Text] [Related]
18. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
19. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
20. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
Wang Y; Zhou Y; Zhou H; Jia G; Liu J; Han B; Cheng Z; Jiang H; Pan S; Sun B
PLoS One; 2012; 7(8):e43826. PubMed ID: 22952775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]